Skip to main content

Fiscal Wizard · Single-issue tearsheet

TEVA / Jun 20, 2026 Run #7237

TEVA

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Composite verdict

C 49.9 / 100
Gated stand-aside 0 drivers · 7 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 15th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -63%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

49.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
EBITDA Margin 100
Revenue Growth (YoY) 0
FCF Margin 100
Days Sales Outstanding 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

7 blocking 5 caution

7 guards active, 43 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for TEVA.